
Opinion|Videos|August 1, 2024
IPF and PDE4B Inhibitors
Author(s)Steven D. Nathan, MD
Dr Nathan highlights the role of PDE4B inhibitors in IPF management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is the rationale for studying the phosphodiesterase 4 (PDE4) inhibitor pathway in idiopathic pulmonary fibrosis (IPF)?
- How do PDE4 inhibitors differ from PDE4B inhibitors?
- Why is this pathway of interest to pulmonologists and patients living with IPF?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Five Ways AI Is Transforming Cancer Care—and Companies That Are Making It Happen
2
Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin
3
Intermountain Spans Time Zones, Cultures to Bring Oncology Care to Alaska
4
NIH F32 Grants Boost Early-Career Researchers’ Success
5

















































